Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 2/20 | 0.40 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7108814 | 0.84 | FABP3 (0.41) | FABP3FABP4FABP5GABRA1GABRB2 | |
| SCHEMBL5469738 | 0.79 | FABP3 (0.40) | FABP3FABP4FABP5GAA | |
| SCHEMBL7207646 | 0.78 | ALDH1A1 (0.38) | FABP3FABP4FABP5GABRA1GABRB2 | |
| SCHEMBL7104860 | 0.77 | FABP3 (0.36) | FABP3FABP4FABP5GABRA1GABRB2 | |
| SCHEMBL7206928 | 0.72 | FABP3 (0.41) | FABP3FABP4FABP5GABRA1GABRB2 | |
| SCHEMBL8706010 | 0.71 | FABP3 (0.38) | FABP3FABP4FABP5GAA | |
| SCHEMBL7109323 | 0.70 | FABP3 (0.39) | FABP3FABP4FABP5GABRA1GABRB2 | |
| SCHEMBL7105200 | 0.70 | FABP3 (0.39) | FABP3FABP4FABP5GABRA1GABRB2 | |
| SCHEMBL7206870 | 0.69 | SRD5A2 (0.39) | FABP3FABP4FABP5GABRA1GABRB2 | |
| SCHEMBL145914 | 0.67 | GABRA1 (0.36) | FABP3FABP4FABP5GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134898-A1 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | HOMAN REYNOLD (US) | 2003-07-17 | — | — | US | claimed |
| EP-0841913-B1 | USE OF SULFAMIC ACID DERIVATIVES, ACYL SULFONAMIDES OR SULFONYL CARBAMATES FOR THE MANUFACTURE OF A MEDICAMENT FOR LOWERING LIPOPROTEIN LEVELS | WARNER LAMBERT CO (US) | 2003-02-05 | — | — | EP | claimed |
| US-20030134898-A1 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | HOMAN REYNOLD (US) | 2003-07-17 | — | — | US | disclosed |
| EP-1281399-A2 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | WARNER-LAMBERT COMPANY (US) | 2003-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134898-A1 | Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production | ACAT2, LCAT, SOAT1 | FABP3 1591/4885FABP4 250/4885FABP5 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.